Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable/Metastatic Melanoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00281541
What this trial is testing

The Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma

Who this might be right for
Melanoma
Astellas Pharma Inc 29
Testing effectiveness (Phase 2)Looking for participantsNCT06359860
What this trial is testing

ST-1898 for Unresectable or Metastatic Melanoma

Who this might be right for
Unresectable or Metastatic Melanoma
Beijing Scitech-Mq Pharmaceuticals Limited 64
Large-scale testing (Phase 3)Study completedNCT01721746
What this trial is testing

Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Who this might be right for
Unresectable or Metastatic Melanoma
Bristol-Myers Squibb 405
Testing effectiveness (Phase 2)Study completedNCT00110994
What this trial is testing

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Who this might be right for
CancerMelanoma
Bayer 101
Early research (Phase 1)Study completedNCT00667641
What this trial is testing

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

Who this might be right for
Breast CancerColorectal CancerHead and Neck Cancer+6 more
University of Medicine and Dentistry of New Jersey 16
Not applicableStudy completedNCT03325257
What this trial is testing

Post-ATU Study of Nivolumab

Who this might be right for
Melanoma
Nantes University Hospital 350
Large-scale testing (Phase 3)Study completedNCT00094653
What this trial is testing

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Who this might be right for
MelanomaMetastases
Bristol-Myers Squibb 1,783
Early research (Phase 1)Ended earlyNCT02419495
What this trial is testing

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Who this might be right for
Advanced Malignant Solid NeoplasmClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+26 more
M.D. Anderson Cancer Center 221
Early research (Phase 1)Study completedNCT00003022
What this trial is testing

Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer

Who this might be right for
Brain and Central Nervous System TumorsIntraocular MelanomaLung Cancer+4 more
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)WithdrawnNCT00803374
What this trial is testing

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

Who this might be right for
Melanoma
Bristol-Myers Squibb
Testing effectiveness (Phase 2)WithdrawnNCT01851408
What this trial is testing

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Who this might be right for
MelanomaRecurrent MelanomaStage III Melanoma+1 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT00289640
What this trial is testing

Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Who this might be right for
Melanoma
Bristol-Myers Squibb 210
Testing effectiveness (Phase 2)Study completedNCT02009397
What this trial is testing

A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients

Who this might be right for
Metastatic Melanoma
University of Louisville 27
Testing effectiveness (Phase 2)Looking for participantsNCT07155317
What this trial is testing

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

Who this might be right for
Advanced Acral MelanomaAdvanced Cutaneous MelanomaAdvanced Mucosal Melanoma+7 more
Emory University 99
Not applicableLooking for participantsNCT06199713
What this trial is testing

Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients

Who this might be right for
MelanomaMelanoma Stage IIIMelanoma Stage IV+1 more
University of Wisconsin, Madison 24
Early research (Phase 1)Study completedNCT01489059
What this trial is testing

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Who this might be right for
Melanoma
Bristol-Myers Squibb 42
Early research (Phase 1)Active Not RecruitingNCT02721459
What this trial is testing

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Who this might be right for
MelanomaSkin Cancer
H. Lee Moffitt Cancer Center and Research Institute 26
Testing effectiveness (Phase 2)Ended earlyNCT00505635
What this trial is testing

Biochemotherapy With Temozolomide for Metastatic Melanoma

Who this might be right for
Melanoma
M.D. Anderson Cancer Center 5
Testing effectiveness (Phase 2)Ended earlyNCT04032704
What this trial is testing

Ladiratuzumab Vedotin in Advanced Solid Tumors

Who this might be right for
Small Cell Lung CancerNon-small Cell Lung Cancer, SquamousNon-small Cell Lung Cancer, Non-squamous+6 more
Seagen Inc. 205
Testing effectiveness (Phase 2)UnknownNCT01409733
What this trial is testing

TACE With Drug Eluting Beads Loaded With Doxorubicin in Liver Metastases From Melanoma Patients

Who this might be right for
Stage IV Melanoma Patients With Unresectable Liver Metastases
Heidelberg University 20
Next Page